Biogelx has appointed Alison Clayton as its new CEO following the retirement of former CEO Mitch Scanlan.

The firm offers ‘hydrogels’ and 3D ‘bioprinting’ to create human tissue model. These are designed to help researchers working in translational science, drug discovery and tissue engineering to “model in vivo conditions in vitro”.

Clayton joins Biogelx following over 25 years in the contract testing business working for Quintiles, Aptuit and Eurofins. The firm said she has a strong focus on operational delivery and strong customer service, and experience in growing business and development of staff.

Clayton brings to the role a degree and PhD from Glasgow University in Pharmacology and strong academic background in basic research, having spent seven years in various post-doctoral research positions.

Chairman John Waddell said: “We are absolutely delighted to have Alison come on board here at Biogelx, her commercial experience coupled with her academic background will help move the company to the next phase of its evolution,” reports Insider.

Clayton added: “I am excited to be joining Biogelx at this time when the applications for the products in 3D Bioprinting and also 3D Cell Culture are growing.

“We have extensive collaborations ongoing with both academia and commercial organisations which further develop the applications for the products maximising their utility within the research and development space.”